Compare DoorDash Inc (DASH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs TransMedics Group Inc — how do they compare? DoorDash Inc trades at $210.01 (market cap $91.86B), while TransMedics Group Inc trades at $89.69 (market cap $3.10B). The key difference: DoorDash Inc is far larger — about 29.6× TransMedics Group Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| DASH | TMDX | |
|---|---|---|
Market Cap | $91.86B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $281.74 | $150.42 |
52-Week Low | $146.60 | $61.99 |
Enterprise Value | $89.82B | $3.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
